Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

A retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension (PAH) In the US

Wednesday, December 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses a retrospective study on the real-world application of monotherapy for pulmonary arterial hypertension (PAH) in the United States. This research aims to shed light on treatment patterns and outcomes for PAH patients. The findings could inform future treatment strategies and improve patient care.
Price reaction · baseline $0.7126 (2024-12-11 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close
+27.7%
day 1 · peak
+30.5%
day 3
+22.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study provides valuable insights into real-world monotherapy use.
  • Focus on pulmonary arterial hypertension (PAH) highlights an important area of research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

A retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension (PAH) In the US
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the focus of the retrospective study?

The study focuses on the real-world use of monotherapy in pulmonary arterial hypertension (PAH) in the US.

What is the significance of this study?

The study aims to provide insights into treatment patterns and outcomes for PAH patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare pulmonary arterial hypertension PAH monotherapy real-world study
Last updated: Dec 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →